| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1:2000-1:5000 | Human,Mouse,Rat |
| Aliases | Aldo-keto reductase family 1, member C1, C9; DD1; DDH; DDH1; H-37; HBAB; MBAB; HAKRC; DD1/DD2; 2-ALPHA-HSD; 20-ALPHA-HSD |
| Entrez GeneID | 1645; |
| WB Predicted band size | 37kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Rat |
| Immunogen | Synthetic peptide corresponding to a region derived from 290-304 amino acids of human aldo-keto reductase family 1, member C1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于AKR1C1抗体的3篇代表性文献的简要概括：
1. **文献名称**：*Aldo-Keto Reductase 1C1 (AKR1C1) as a Target for Prostate Cancer Biomarker Discovery*
**作者**：Penning TM, et al.
**摘要**：该研究利用AKR1C1特异性抗体，发现其在前列腺癌细胞中高表达，并参与雄激素代谢，提示其可作为前列腺癌诊断或治疗的潜在靶点。
2. **文献名称**：*AKR1C1-Mediated Drug Resistance in Breast Cancer: Role of Oxidative Stress*
**作者**：Matsumoto R, et al.
**摘要**：通过免疫组化分析，研究者发现AKR1C1抗体标记的蛋白在乳腺癌组织中表达升高，其通过调节氧化应激通路增强癌细胞对化疗药物(如阿霉素)的耐药性。
3. **文献名称**：*Immunohistochemical Detection of AKR1C1 in Endometrial Cancer: Correlation with Hormone Receptor Status*
**作者**：Lin HK, et al.
**摘要**：研究采用AKR1C1抗体检测子宫内膜癌组织，发现其表达水平与雌激素受体(ER)正相关，提示其在激素依赖性肿瘤进展中的作用。
以上文献聚焦于AKR1C1抗体在疾病模型中的应用，涵盖癌症诊断、耐药机制及激素代谢调控等领域。如需具体文献来源，建议通过PubMed或Google Scholar检索标题及作者。
The AKR1C1 antibody is a crucial tool in studying the aldo-keto reductase family 1 member C1 (AKR1C1), an enzyme involved in steroid hormone metabolism and xenobiotic detoxification. AKR1C1 catalyzes the reduction of ketosteroids, prostaglandins, and other carbonyl-containing compounds, playing roles in hormone regulation, inflammation, and drug metabolism. It is implicated in various pathologies, including cancer, endocrine disorders, and metabolic diseases. Research has highlighted its overexpression in hormone-dependent cancers (e.g., breast, prostate), where it may influence tumor progression by modulating steroid hormone levels or activating carcinogens.
AKR1C1 antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect protein expression, localization, and quantification in tissues or cell lines. These antibodies aid in exploring AKR1C1's physiological functions, pathological roles, and interactions with signaling pathways. Specificity is critical due to high sequence homology among AKR1C isoforms (AKR1C1-C4), requiring validation via knockout controls or epitope mapping.
Recent studies focus on AKR1C1's potential as a therapeutic target or biomarker, particularly in cancer drug resistance and hormone-related diseases. Commercial AKR1C1 antibodies are typically raised against recombinant protein fragments or synthetic peptides, with validation across species and applications. Researchers must verify antibody performance in their experimental systems to ensure reliability.
×
